1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow ST-segment Elevation Myocardial Infarction (STEMI): new trials by email Literature Review of ST-segment Elevation Myocardial Infarction (STEMI) trials Research Report on ST-segment Elevation Myocardial Infarction (STEMI)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI Butylphthalide, Butylphthalide placebo - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 3 | Not yet recruiting | Xiangya Hospital of Central South University | 40 | 2024-12-01 | 2024-11-26 |
| Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction Dapagliflozin, Placebo - ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus | Phase 3 | Unknown | Hospital Clinic of Barcelona | 54 | 2021-05-30 | 2025-02-19 |
| Pharmacoinvasive Therapy With Prourokinase Prourokinase, Placebo - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 2 / Phase 3 | Completed | Suzhou Landing Pharmaceuticals | 197 | 2008-11-01 | 2012-07-27 |
ST Elevation Myocardial Infarction (3) · Diabetes Mellitus (1) · Heart Failure (1)
Cardiovascular Diseases (3) · Heart Diseases (3) · Infarction (3) · Ischemia (3) · Myocardial Infarction (3) · Myocardial Ischemia (3) · Necrosis (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
3-n-butylphthalide (1) · dapagliflozin (1) · saruplase (1)
Hospital Clinic of Barcelona (1) · Suzhou Landing Pharmaceuticals (1) · Xiangya Hospital of Central South University (1)
China (1) · Spain (1)
Luis Ortega, MD, PhD (1) · Salvatore Brugaletta, MD, PhD (1)
2018 (1)